华润医药(03320.HK)附属东阿阿胶料去年盈转亏蚀3.34亿人币
华润医药(03320.HK)公布,附属东阿阿胶公布去年业绩预告,料将录3.34亿元人民币(下同)至4.59亿元亏损,对比2018年全年录得纯利20.85亿元。公司表示,主要原因是近年来受整体宏观环境以及市场对价值回归预期逐渐降低等因素影响,东阿阿胶渠道库存出现持续积压。为避免企业长期良性健康受到不利影响,去年东阿阿胶主要侧重於清理渠道库存,主动严格控制发货、全面压缩渠道库存数量,尤其在下半年进一步加大了渠道库存的清理力度,因而对经营业绩影响有所加大。
公司表示,2018年东阿阿胶对公司整体收入及纯利贡献约为5.6%及13%,是次东阿阿胶业绩由盈转亏或会对公司的全年业绩带来一定影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.